All Title Author
Keywords Abstract

Lipid Based Therapy for Ulcerative Colitis—Modulation of Intestinal Mucus Membrane Phospholipids as a Tool to Influence Inflammation

DOI: 10.3390/ijms11104149

Keywords: phospholipids, phosphatidylcholine, mucosal barrier, ulcerative colitis, phospholipase A2

Full-Text   Cite this paper   Add to My Lib


Ulcerative colitis (UC) is the result of an inappropriate colonic inflammatory response triggered by environmental and genetic factors. We have recently shown that mucus from UC patients has a decreased phosphatidylcholine (PC) content, while clinical trials revealed that therapeutic addition of PC to the colonic mucus alleviated the inflammatory activity. The mechanisms behind this are still unclear. We hypothesized that PC has at least two possible functions in the intestine: First, it establishes the surface hydrophobicity of the mucus and therefore protects the underlying tissue against intraluminal aggressors; recent experiments on surgical specimens revealed reduced surface tension and hydrophobicity in UC patients. Second, mucus phospholipids might also be integrated into the plasma membranes of enterocytes and thereby influence the signaling state of the mucosa. PC has been shown to inhibit TNF-α induced pro-inflammatory responses including: (1) assembly of plasma membrane actin; (2)?activation of MAP kinases ERK and p38; and (3) activation of NF-κB and synthesis of pro-inflammatory gene products. Other phospholipids like phosphatidylethanolamine or sphingomyelin ?had no effect. PC also inhibited latex bead phagosome actin assembly, killing of M. tuberculosis in macrophages, and sphingosine-1-phosphate induced actin assembly in macrophages. Collectively, these results provide a molecular foundation that shows PC, firstly, as an anti-inflammatory, and secondly, as a surface hydrophobicity increasing compound with promising therapeutic potential in the treatment of inflammatory bowel disease.


[1]  Best, CH; Hershey, JM; Huntsman, ME. The effect of lecithine on fat deposition in the liver of the normal rat. J. Physiol?1932, 75, 56–66.
[2]  Eros, G; Ibrahim, S; Siebert, N; Boros, M; Vollmar, B. Oral phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid arthritis. Arthritis Res. Ther?2009, 11, R43.
[3]  Eros, G; Varga, G; Varadi, R; Czobel, M; Kaszaki, J; Ghyczy, M; Boros, M. Anti-inflammatory action of a phosphatidylcholine, phosphatidylethanolamine and N-acylphosphatidylethanolamine-enriched diet in carrageenan-induced pleurisy. Eur. Surg. Res?2009, 42, 40–48.
[4]  Lichtenberger, LM; Graziani, LA; Dial, EJ; Butler, BD; Hills, BA. Role of surface-active phospholipids in gastric cytoprotection. Science?1983, 219, 1327–1329.
[5]  Lichtenberger, LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu. Rev. Physiol?1995, 57, 565–583.
[6]  Zhou, Y; Dial, EJ; Doyen, R; Lichtenberger, LM. Effect of indomethacin on bile acid-phospholipid interactions: Implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs. Am. J. Physiol. Gastrointest. Liver Physiol?2010, 298, G722–G731.
[7]  Lugea, A; Antolin, M; Mourelle, M; Guarner, F; Malagelada, JR. Deranged hydrophobic barrier of the rat gastroduodenal mucosa after parenteral nonsteroidal anti-inflammatory drugs. Gastroenterology?1997, 112, 1931–1939.
[8]  Lichtenberger, LM; Romero, JJ; Dial, EJ. Gastrointestinal safety and therapeutic efficacy of parenterally administered phosphatidylcholine-associated indomethacin in rodent model systems. Br. J. Pharmacol?2009, 157, 252–257.
[9]  Lanza, FL; Marathi, UK; Anand, BS; Lichtenberger, LM. Clinical trial: Comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment Pharmacol. Ther?2008, 28, 431–442.
[10]  Cryer, B; Bhatt, DL; Lanza, FL; Dong, J-F; Lichtenberger, LM; Marathi, UK. Reduction of gastroduodenal ulceration with aspirin-phosphatidylcholine complex versus aspirin—potential importance of local mucosal injury. Gastroenterology?2010, 138, S497.
[11]  Podolsky, DK. Inflammatory bowel disease. N. Engl. J. Med?2002, 347, 417–429.
[12]  Sartor, RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics. Gastroenterology?2004, 126, 1620–1633.
[13]  Backhed, F; Ley, RE; Sonnenburg, JL; Peterson, DA; Gordon, JI. Host-bacterial mutualism in the human intestine. Science?2005, 307, 1915–1920.
[14]  Rutgeerts, P; Goboes, K; Peeters, M; Hiele, M; Penninckx, F; Aerts, R; Kerremans, R; Vantrappen, G. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet?1991, 338, 771–774.
[15]  Duchmann, R; May, E; Heike, M; Knolle, P; Neurath, M; Meyer zum Buschenfelde, KH. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut?1999, 44, 812–818.
[16]  Swidsinski, A; Ladhoff, A; Pernthaler, A; Swidsinski, S; Loening-Baucke, V; Ortner, M; Weber, J; Hoffmann, U; Schreiber, S; Dietel, M; Lochs, H. Mucosal flora in inflammatory bowel disease. Gastroenterology?2002, 122, 44–54.
[17]  Wen, Z; Fiocchi, C. Inflammatory bowel disease: Autoimmune or immune-mediated pathogenesis? Clin. Dev. Immunol?2004, 11, 195–204.
[18]  Pullan, RD; Thomas, GA; Rhodes, M; Newcombe, RG; Williams, GT; Allen, A; Rhodes, J. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut?1994, 35, 353–359.
[19]  Einerhand, AW; Renes, IB; Makkink, MK; van der Sluis, M; Buller, HA; Dekker, J. Role of mucins in inflammatory bowel disease: Important lessons from experimental models. Eur. J. Gastroenterol. Hepatol?2002, 14, 757–765.
[20]  Ehehalt, R; Wagenblast, J; Erben, G; Lehmann, WD; Hinz, U; Merle, U; Stremmel, W. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand. J. Gastroenterol?2004, 39, 737–742.
[21]  Braun, A; Treede, I; Gotthardt, D; Tietje, A; Zahn, A; Ruhwald, R; Schoenfeld, U; Welsch, T; Kienle, P; Erben, G; Lehmann, WD; Fuellekrug, J; Stremmel, W; Ehehalt, R. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: A clue to pathogenesis. Inflamm. Bowel. Dis?2009, 15, 1705–1720.
[22]  Longman, RJ; Poulsom, R; Corfield, AP; Warren, BF; Wright, NA; Thomas, MG. Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis. J. Histochem. Cytochem?2006, 54, 1335–1348.
[23]  Wehkamp, J; Schmid, M; Stange, EF. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr. Opin. Gastroenterol?2007, 23, 370–378.
[24]  Schulzke, JD; Ploeger, S; Amasheh, M; Fromm, A; Zeissig, S; Troeger, H; Richter, J; Bojarski, C; Schumann, M; Fromm, M. Epithelial tight junctions in intestinal inflammation. Ann. N.Y. Acad. Sci?2009, 1165, 294–300.
[25]  Langmann, T; Moehle, C; Mauerer, R; Scharl, M; Liebisch, G; Zahn, A; Stremmel, W; Schmitz, G. Loss of detoxification in inflammatory bowel disease: Dysregulation of pregnane X receptor target genes. Gastroenterology?2004, 127, 26–40.
[26]  Macfarlane, GT; Blackett, KL; Nakayama, T; Steed, H; Macfarlane, S. The gut microbiota in inflammatory bowel disease. Curr. Pharm. Des?2009, 15, 1528–1536.
[27]  Fabia, R; Ar'Rajab, A; Willen, R; Andersson, R; Ahren, B; Larsson, K; Bengmark, S. Effects of phosphatidylcholine and phosphatidylinositol on acetic-acid-induced colitis in the rat. Digestion?1992, 53, 35–44.
[28]  Fabia, R; Ar'Rajab, A; Willen, R; Andersson, R; Bengmark, S. Effect of putative phospholipase A2 inhibitors on acetic acid-induced acute colitis in the rat. Br. J. Surg?1993, 80, 1199–1204.
[29]  Tatsumi, Y; Lichtenberger, LM. Molecular association of trinitrobenzenesulfonic acid and surface phospholipids in the development of colitis in rats. Gastroenterology?1996, 110, 780–789.
[30]  Mourelle, M; Guarner, F; Malagelada, JR. Polyunsaturated phosphatidylcholine prevents stricture formation in a rat model of colitis. Gastroenterology?1996, 110, 1093–1097.
[31]  Barrios, JM; Lichtenberger, LM. Role of biliary phosphatidylcholine in bile acid protection and NSAID injury of the ileal mucosa in rats. Gastroenterology?2000, 118, 1179–1186.
[32]  Lugea, A; Salas, A; Casalot, J; Guarner, F; Malagelada, JR. Surface hydrophobicity of the rat colonic mucosa is a defensive barrier against macromolecules and toxins. Gut?2000, 46, 515–521.
[33]  Sturm, A; Zeeh, J; Sudermann, T; Rath, H; Gerken, G; Dignass, AU. Lisofylline and lysophospholipids ameliorate experimental colitis in rats. Digestion?2002, 66, 23–29.
[34]  Treede, I; Braun, A; Sparla, R; Kuhnel, M; Giese, T; Turner, JR; Anes, E; Kulaksiz, H; Fullekrug, J; Stremmel, W; Griffiths, G; Ehehalt, R. Anti-inflammatory effects of phosphatidylcholine. J. Biol. Chem?2007, 282, 27155–27164.
[35]  Anes, E; Kuhnel, MP; Bos, E; Moniz-Pereira, J; Habermann, A; Griffiths, G. Selected lipids activate phagosome actin assembly and maturation resulting in killing of pathogenic mycobacteria. Nat. Cell Biol?2003, 5, 793–802.
[36]  Gutierrez, MG; Gonzalez, AP; Anes, E; Griffiths, G. Role of lipids in killing mycobacteria by macrophages: Evidence for NF-kappaB-dependent and -independent killing induced by different lipids. Cell Microbiol?2009, 11, 406–420.
[37]  Stremmel, W; Merle, U; Zahn, A; Autschbach, F; Hinz, U; Ehehalt, R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut?2005, 54, 966–971.
[38]  Tromm, A; Griga, T; May, B. Oral mesalazine for the treatment of Crohn's disease: Clinical efficacy with respect to pharmacokinetic properties. Hepatogastroenterology?1999, 46, 3124–3135.
[39]  Stremmel, W; Braun, A; Hanemann, A; Ehehalt, R; Autschbach, F; Karner, M. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: A randomized, double-blinded, dose finding study. J. Clin. Gastroenterol?2010, 44, e101–107.
[40]  Stremmel, W; Ehehalt, R; Autschbach, F; Karner, M. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: A randomized trial. Ann. Int. Med?2007, 147, 603–610.
[41]  Parlesak, A; Schaeckeler, S; Moser, L; Bode, C. Conjugated primary bile salts reduce permeability of endotoxin through intestinal epithelial cells and synergize with phosphatidylcholine in suppression of inflammatory cytokine production. Crit. Care Med?2007, 35, 2367–2374.
[42]  Dial, EJ; Tran, DM; Romero, JJ; Zayat, M; Lichtenberger, LM. A direct role for secretory phospholipase A2 and lyso-phosphatidylcholine in the mediation of lipopolysaccharide-induced gastric injury. Shock?2010, 33, 634–638.
[43]  Hills, BA. Surface-active phospholipid: A Pandora's box of clinical applications. Part II. Barrier and lubricating properties. Int. Med. J?2002, 32, 242–251.
[44]  Braun, A; Schoenfeld, U; Welsch, T; Kadmon, M; Funke, B; Autschbach, F; Grunze, M; Stremmel, W; Kienle, P; Ehehalt, R. The surface hydrophobicity of the colonic mucosa is reduced in ulcerative colitis. J. Crohn's Colitis?2010, 4, S13–S120.
[45]  Hurley, JH; Tsujishita, Y; Pearson, MA. Floundering about at cell membranes: A structural view of phospholipid signaling. Curr. Opin. Struct. Biol?2000, 10, 737–743.
[46]  Alpy, F; Tomasetto, C. Give lipids a START: The StAR-related lipid transfer (START) domain in mammals. J. Cell Sci?2005, 118, 2791–2801.
[47]  Medina-Gomez, G; Gray, SL; Yetukuri, L; Shimomura, K; Virtue, S; Campbell, M; Curtis, RK; Jimenez-Linan, M; Blount, M; Yeo, GS; Lopez, M; Seppanen-Laakso, T; Ashcroft, FM; Oresic, M; Vidal-Puig, A. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet?2007, 3, e64.
[48]  Chakravarthy, MV; Lodhi, IJ; Yin, L; Malapaka, RR; Xu, HE; Turk, J; Semenkovich, CF. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell?2009, 138, 476–488.
[49]  Chen, X; Xun, K; Chen, L; Wang, Y. TNF-alpha, a potent lipid metabolism regulator. Cell Biochem. Funct?2009, 27, 407–416.
[50]  Targan, SR; Hanauer, SB; van Deventer, SJ; Mayer, L; Present, DH; Braakman, T; DeWoody, KL; Schaible, TF; Rutgeerts, PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med?1997, 337, 1029–1035.
[51]  van Deventer, SJ. Tumour necrosis factor and Crohn's disease. Gut?1997, 40, 443–448.
[52]  Rutgeerts, P; Sandborn, WJ; Feagan, BG; Reinisch, W; Olson, A; Johanns, J; Travers, S; Rachmilewitz, D; Hanauer, SB; Lichtenstein, GR; de Villiers, WJ; Present, D; Sands, BE; Colombel, JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med?2005, 353, 2462–2476.
[53]  Hueber, AO. Role of membrane microdomain rafts in TNFR-mediated signal transduction. Cell Death Differ?2003, 10, 7–9.
[54]  Simons, K; Ehehalt, R. Cholesterol, lipid rafts, and disease. J. Clin. Invest?2002, 110, 597–603.
[55]  Lingwood, D; Simons, K. Lipid rafts as a membrane-organizing principle. Science?2010, 327, 46–50.
[56]  Triantafilou, M; Morath, S; Mackie, A; Hartung, T; Triantafilou, K. Lateral diffusion of Toll-like receptors reveals that they are transiently confined within lipid rafts on the plasma membrane. J. Cell Sci?2004, 117, 4007–4014.
[57]  Legler, DF; Micheau, O; Doucey, MA; Tschopp, J; Bron, C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity?2003, 18, 655–664.
[58]  Cottin, V; Doan, JE; Riches, DW. Restricted localization of the TNF receptor CD120a to lipid rafts: A novel role for the death domain. J. Immunol?2002, 168, 4095–4102.
[59]  Treede, I; Braun, A; Jeliaskova, P; Giese, T; Fullekrug, J; Griffiths, G; Stremmel, W; Ehehalt, R. TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol?2009, 9, 53.
[60]  Nishida, T; Miwa, H; Shigematsu, A; Yamamoto, M; Iida, M; Fujishima, M. Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis. Gut?1987, 28, 1002–1007.
[61]  Ehehalt, R; Braun, A; Karner, M; Fullekrug, J; Stremmel, W. Phosphatidylcholine as a constituent in the colonic mucosal barrier--physiological and clinical relevance. Biochim. Biophys. Acta?2010, 1801, 983–993.
[62]  Clark, JD; Lin, LL; Kriz, RW; Ramesha, CS; Sultzman, LA; Lin, AY; Milona, N; Knopf, JL. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP. Cell?1991, 65, 1043–1051.
[63]  Hirabayashi, T; Murayama, T; Shimizu, T. Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol. Pharm. Bull?2004, 27, 1168–1173.
[64]  Yu, W; Bozza, PT; Tzizik, DM; Gray, JP; Cassara, J; Dvorak, AM; Weller, PF. Co-compartmentalization of MAP kinases and cytosolic phospholipase A2 at cytoplasmic arachidonate-rich lipid bodies. Am. J. Pathol?1998, 152, 759–769.
[65]  Gentile, LB; Piva, B; Capizzani, BC; Furlaneto, LG; Moreira, LS; Zamith-Miranda, D; Diaz, BL. Hypertonic environment elicits cyclooxygenase-2-driven prostaglandin E2 generation by colon cancer cells: Role of cytosolic phospholipase A2-alpha and kinase signaling pathways. Prostagl. Leukot Essent Fat. Ac?2010, 82, 131–139.
[66]  Takaku, K; Sonoshita, M; Sasaki, N; Uozumi, N; Doi, Y; Shimizu, T; Taketo, MM. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J. Biol. Chem?2000, 275, 34013–34016.
[67]  Krimsky, M; Yedgar, S; Aptekar, L; Schwob, O; Goshen, G; Gruzman, A; Sasson, S; Ligumsky, M. Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor. Am. J. Physiol. Gastrointest. Liver Physiol?2003, 285, G586–592.
[68]  Adler, DH; Cogan, JD; Phillips, JA, 3rd; Schnetz-Boutaud, N; Milne, GL; Iverson, T; Stein, JA; Brenner, DA; Morrow, JD; Boutaud, O; Oates, JA. Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J. Clin. Invest?2008, 118, 2121–2131.
[69]  Yedgar, S; Cohen, Y; Shoseyov, D. Control of phospholipase A2 activities for the treatment of inflammatory conditions. Biochim. Biophys. Acta?2006, 1761, 1373–1382.
[70]  Sawai, T; Lampman, R; Hua, Y; Segura, B; Drongowski, RA; Coran, AG; Harmon, CM. Lysophosphatidylcholine alters enterocyte monolayer permeability via a protein kinase C/Ca2+ mechanism. Pediatr. Surg. Int?2002, 18, 591–594.
[71]  Tries, S; Neupert, W; Laufer, S. The mechanism of action of the new antiinflammatory compound ML3000: Inhibition of 5-LOX and COX-1/2. Inflamm. Res?2002, 51, 135–143.
[72]  Panel, V; Boelle, PY; Ayala-Sanmartin, J; Jouniaux, AM; Hamelin, R; Masliah, J; Trugnan, G; Flejou, JF; Wendum, D. Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Cancer Lett?2006, 243, 255–263.


comments powered by Disqus